We discuss the case of a 46-year-old male patient presenting to the emergency department with acute inferior myocardial infarction. Coronary angiography demonstrated a vasospasm of the left main coronary artery and proximal segment of the left anterior descending artery. Furthermore, a thrombotic total occlusion was ascertained in the right coronary artery. The vasospasm in the left main and left anterior descending artery disappeared after nitrate administration. We successfully implanted a stent to the thrombotic occlusion in the right coronary artery after predilatation. On detailed questioning, the patient stated that ozonated autohemotherapy had been applied that morning in a private clinic for the revitalization and regeneration of tissues. The patient did not have any traditional atherosclerotic risk factors. He denied any history of cardiac complaint. Factor V Leiden, prothrombin 20210 and MTHFR a1298c and c677t mutations were investigated and found to be negative except for MTHFR a1298c, which was a heterozygote. The levels of antithrombin III, homocysteine and protein C and S were all within normal ranges. Ozone as a medical therapy has been used in many medical conditions; unfortunately, however, like every other therapy, ozone therapy has side effects. The literature concerning ozone therapy supports possible strong vasoconstrictor and prothrombotic effects of ozone therapy, further supporting our suggestion that ozone can lead to acute coronary syndromes in human beings. In conclusion, to our knowledge, our case report reveals a possible complication of ozone therapy that has never been reported before. We think that this article will raise the awareness of the possibility of thrombotic complications after ozonated autohemotherapy.

Keywords:
Myocardial infarction, Ozone, Ozonated autohemotherapy
1.
Bocci V: Ozone as Janus: this controversial gas can be either toxic or medically useful. Mediators Inflamm 2004;13:3-11.
2.
Bocci V, Zanardi I, Travagli V: Oxygen/ozone as a medical gas mixture. A critical evaluation of the various methods clarifies positive and negative aspects. Med Gas Res 2011;1:6.
3.
Rokitansky O, Rokitansky A, Steiner J, Trubel W, Viebahn R, Washuttl J: Die Ozontherapie bei peripheren, arteriellen Durchblutungsstörungen: Klinik, biochemische und blutgasanalytische Untersuchungen; in Wasser IOA (ed). Ozon-Weltkongress, Berlin, 1981, pp 53-75.
4.
Giunta R, Coppola C, Luongo C, et al: Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann Hematol 2001;80:745-748.
5.
Tylicki L, Niewglowski T, Biedunkiewicz B, Burakoski S, Rutkows B: Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs-pilot study. Int J Artif Organs 2001;24:79-82.
6.
Burgassi S, Zanardi I, Travagli V, Montomoli E, Bocci V: How much ozone bactercidal activity is compromised by plasma components? J Appl Microbiol 2009;106:1715-1721.
7.
Maresca M, Colao C, Leoncini G: Generation of hydrogen peroxide in resting and activated platelets. Cell Biochem Funct 1992;10:79-85.
8.
Iuliano L, Colavita AR, Leo R, Pratico D, Violi F: Oxygen free radicals and platelet activation. Free Radic Biol Med 1997;22:999-1006.
9.
Bocci V, Valacchi G, Rossi R, Giustarini D, Paccagnini E, Pucci AM, DiSimplicio P: Studies on the biological effects of ozone: effects of ozone on human platelets. Platelets 1999;10:110-116.
10.
Valacchi G, Bocci V: Studies on the biological effects of ozone: release of factors from human endothelial cells. Mediat Inflamm 2000;9:271-276.
11.
Coppola A, Coppola L, Luongo C, Arciello A, Cacciapuoti F, Lama D, et al: Ozonized autohemotransfusion does not affect arterial vasodilatation in patients with peripheral arterial disease. Int J Angiol 2007;16:7-11.
12.
Ruidavets JB, Cournot M, Cassadou S, Giroux M, Meybeck M, Ferrieres J: Ozone air pollution is associated with acute myocardial infarction. Circulation 2005;111:563-569.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.